Yahoo Finance

Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid ...
NBC News

Intellipharmaceutics Announces Third Quarter 2010 Results

TORONTO, Oct. 15, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel or ...
Yahoo Finance

Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid ...
Nasdaq

Intellipharmaceutics Announces Change in Venue for The Company’s Annual General Meeting Scheduled To Be Held on December 23, 2020

TORONTO, ON / ACCESSWIRE / December 15, 2020 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the ...
equities

Intellipharmaceutics Receives FDA Approval for Focalin XR Generic

Because it can be a long, expensive path to commercializing a drug, there are a lot of small drug companies that coast under the radar of Wall Street players that see the risk as outweighing the ...
Nasdaq

Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement

TORONTO, ON / ACCESSWIRE / April 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the ...
Seeking Alpha

Intellipharmaceutics Announces Downgrade to OTC Expert Market

TORONTO, ON / ACCESSWIRE / June 14, 2024 / Intellipharmaceutics International Inc. (IPCIF) and (TSX:IPCI.H) ("Intellipharmaceutics" or the "Company"), announced today that its common stock, currently ...
FiercePharma

Intellipharmaceutics Provides Update on Activities Related to Generic Seroquel XR(R)

TORONTO, May 26, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), today announced the following with regard to its generic drug commercialization activities.
Becker's Hospital Review

Intellipharmaceutics earns FDA approval for generic epilepsy drug

Here are four things to know. 1. Levetiracetam is intended to treat partial onset seizures related to epilepsy. 2. The tablets are a generic equivalent to UCB’s brand name drug Keppra XR. 3. Sales of ...
GEN

Vasogen to Combine with IntelliPharmaCeutics and Focus on Controlled-Release Products

Deal marks the culmination of Vasogen’s search for alternatives after it halted development due to lack of capital. Vasogen and privately held IntelliPharmaCeutics (IPC) inked a merger agreement to ...
Stockhouse

Intellipharmaceutics Announces its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form and its Management Cease Trade Order Application

TORONTO, Feb. 6, 2023 /CNW/ - Intellipharmaceutics International Inc. (OTCQB: IPCIF) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, ...